Beyond Reality: Which Parts of the Ketamine Experience Matter?

A Question Born From Observation

My interest in this question did not begin in a laboratory.

It developed through years of observing the environment and patient experience surrounding ketamine treatment at Ketamine Lounge.

Again and again, our team has heard patients describe dramatically different experiences during treatment.

Some report relatively mild changes in perception or a feeling of separation from their surroundings.

Others describe losing their ordinary sense of time or body.

Some experience a profound dissolution of the boundaries between themselves and everything around them.

And occasionally, people describe experiences they interpret as deeply mystical or spiritual—encounters with an overwhelming sense of unity, transcendence, interconnectedness, meaning or something they struggle to put into words.

Our team has repeatedly observed that these deeper altered-state experiences appear to accompany some of the most meaningful therapeutic responses we see.

That observation has strongly influenced the questions we ask about ketamine treatment.

But observation is not proof.

It cannot establish whether the experience caused the therapeutic response, whether both resulted from another underlying mechanism or whether other variables were responsible.

That distinction has become increasingly important because researchers are now asking versions of the same question:

Does the subjective ketamine experience itself matter?

And perhaps more precisely:

Which parts of the experience matter?

Ketamine Does More Than Produce Dissociation

Ketamine is a dissociative anesthetic.

At doses used in psychiatric treatment, it can produce changes in perception, body awareness, time, space, thought and sense of self.

But the word dissociation can be misleading because it is often used to describe experiences that differ enormously in character and intensity.

One person might feel slightly detached from the room.

Another might experience their body as distant or unfamiliar.

Another might temporarily lose their ordinary sense of being a separate self.

And another might describe an experience of profound unity or transcendence that they interpret as mystical or spiritual.

Calling all of these simply “dissociation” risks collapsing very different phenomena into a single clinical term.

That may be one reason research examining whether dissociation predicts therapeutic response has produced inconsistent results.

A systematic review published in a 2025 journal issue examined 29 studies investigating ketamine-induced altered states of consciousness and clinical outcomes. Fifteen found a positive relationship, 13 found no relationship and one reported a negative association. Among the 25 studies specifically involving intravenous ketamine, 14 reported a positive relationship between psychoactive effects and therapeutic outcomes. (Systematic review)

That is not evidence that the altered state is irrelevant.

Nor is it evidence that it is essential.

It suggests that we may still be asking the question too broadly.

Dissociation Is Not One Experience

Researchers frequently measure ketamine-related dissociation using the Clinician-Administered Dissociative States Scale, or CADSS.

The scale measures phenomena including:

depersonalization — changes in the ordinary experience of oneself;

derealization — changes in how real or familiar the external world feels;

and amnesia — disruptions in memory.

These are useful clinical constructs.

But a conventional dissociation scale was not designed specifically to capture the full phenomenology of profound altered states, including experiences of unity, transcendence, sacredness, ineffability or deep personal meaning.

That distinction may matter.

Some studies have found associations between dissociation and antidepressant response.

An NIH analysis, for example, found that the depersonalization component of dissociation was the component most consistently associated with antidepressant improvement following ketamine.

Another randomized-trial analysis found a relationship between increasing CADSS scores and antidepressant improvement 24 hours after ketamine or esketamine within a particular range of dissociation scores, although the study was not originally designed to test that relationship as its primary outcome.

Other research has found no clinically meaningful relationship.

An analysis combining 576 participants from two esketamine trials found no clinically significant association between acute dissociation measured by CADSS and antidepressant efficacy. (TRANSFORM-1/TRANSFORM-2 analysis)

The literature therefore does not support a simple conclusion that:

more dissociation = better outcome.

But perhaps “how dissociated was the patient?” is not the only question worth asking.

An Altered-State Spectrum

One way of thinking about the ketamine experience is as a spectrum rather than a binary event.

Ordinary consciousness

↓

Altered perception

↓

Dissociation / detachment

↓

Profound changes in self, body, time and space

↓

Ego dissolution

↓

Mystical or spiritual-type experience

This is not a validated clinical staging system.

It is a conceptual model for understanding why the word dissociation may be insufficient to describe the range of experiences people report.

A mystical ketamine experience does not occur while consciousness remains completely ordinary.

It involves an altered state.

But the reverse does not follow.

Not every altered or dissociative state becomes mystical.

That distinction may prove important.

What Is a Mystical-Type Experience?

Science can study mystical experiences without deciding whether their spiritual interpretations are objectively true.

Researchers typically approach them phenomenologically: by studying what people report experiencing.

Common features include:

unity or interconnectedness

transcendence of ordinary time and space

loss or weakening of ordinary self-boundaries

deeply positive emotion

a sense of sacredness

ineffability

and sometimes a powerful sense that the experience carries unusual truth or significance.

The term ego dissolution is often used to describe the temporary weakening or disappearance of the ordinary boundary between self and world.

Some people interpret these experiences psychologically.

Others understand them spiritually.

Some describe encountering God, universal consciousness, another realm or a fundamental interconnectedness between themselves and existence.

Science can document those reports.

It cannot currently establish whether the metaphysical interpretation attached to them is objectively true.

That does not make the experience psychologically meaningless.

A person's interpretation of an experience can have profound consequences regardless of whether science can validate its ultimate explanation.

Can Ketamine Produce Mystical Experiences?

Yes.

Although ketamine is pharmacologically different from classic serotonergic psychedelics such as psilocybin and LSD, research increasingly documents psychedelic-like and mystical-type experiences following ketamine administration.

A 2025 retrospective exploratory study examined 60 veterans with treatment-resistant depression across 189 ketamine or esketamine treatments. (Veterans study)

Complete mystical experiences, as measured using the Revised Mystical Experience Questionnaire, occurred in approximately 17% of esketamine sessions and 18% of racemic ketamine sessions.

Among people receiving racemic ketamine, higher doses were associated with higher mystical-experience scores. The researchers concluded that ketamine can occasion mystical experiences and called for further investigation into whether those experiences contribute therapeutically.

That final distinction matters.

We know ketamine can produce mystical experiences.

We do not yet know with certainty what therapeutic role those experiences play.

The Case That the Experience Matters

There are several reasons researchers take this possibility seriously.

Across psychedelic research more broadly, the intensity or quality of mystical-type experiences has repeatedly been associated with subsequent therapeutic outcomes.

Ketamine research is less consistent, but some studies have also found relationships between particular altered-state phenomena and clinical improvement.

Our observations at Ketamine Lounge point in the same general direction.

Over years of being involved with the treatment environment and patient experience, our team has repeatedly seen patients emerge from deeper altered states describing changes that appear qualitatively different from simple symptom reduction.

They may speak about seeing their life from a different perspective.

Feeling separated from longstanding patterns of thought.

Experiencing forgiveness.

Confronting grief.

Losing, temporarily, their ordinary sense of self.

Feeling profoundly connected to family, humanity, nature or existence.

Or encountering something they understand as spiritual.

Some of the most meaningful therapeutic responses we have observed have accompanied experiences like these.

That does not establish causation.

But neither should observations like these automatically be dismissed simply because they are subjective.

They generate a legitimate scientific question.

The Case That the Experience Doesn't Matter

There is also a strong competing explanation.

Ketamine produces significant biological effects associated with its antidepressant action.

The subjective experience could simply occur alongside those effects.

Imagine a drug simultaneously producing:

A — biological mechanisms responsible for antidepressant improvement

and

B — an unusual subjective experience.

If both become more pronounced with drug exposure, A and B could correlate even if B does not cause A.

In that scenario:

the experience accompanies the medicine without being the medicine.

This possibility is supported by studies that have failed to find a consistent relationship between dissociation and antidepressant response.

A systematic review of ketamine's acute psychoactive effects concluded that total CADSS dissociation scores were not consistently associated with antidepressant outcomes and that the literature was too limited and heterogeneous for definitive conclusions.

A large esketamine analysis similarly found no clinically significant relationship between dissociation and antidepressant efficacy.

And a 2026 post hoc analysis of an open-label study involving 39 patients receiving a single intravenous ketamine infusion found that dissociation measured by CADSS during the infusion did not differ significantly between patients classified as treatment responders and nonresponders at Day 7. (39-patient study)

The pharmacological explanation therefore cannot be dismissed.

Or Are We Measuring the Wrong Thing?

There is another possibility.

Perhaps the inconsistent literature does not mean subjective experience is unimportant.

Perhaps the instruments most commonly used have not been measuring the aspects of experience that matter.

A patient who reports:

“The room felt strange and my body seemed distant.”

and someone who reports:

“My sense of being a separate self disappeared and I experienced an overwhelming feeling of connection and meaning.”

may both register as experiencing an altered state.

Psychologically, however, those experiences are not necessarily equivalent.

This could help explain why research focused narrowly on conventional dissociation produces mixed results while newer research is increasingly examining broader dimensions such as:

mystical experience

ego dissolution

emotional breakthrough

psychological insight

connectedness

and meaningfulness.

The relevant variable may ultimately prove not to be whether a person dissociates.

It may be the quality and phenomenology of the altered state.

That remains a hypothesis.

But it is becoming a testable one.

Biology or Experience?

The debate is sometimes framed as though only one explanation can be correct.

Either ketamine works through biology.

Or it works through experience.

That may be a false choice.

A third possibility is that the two interact.

Ketamine may initiate biological processes associated with rapid antidepressant effects and neuroplasticity.

At the same time, the altered state may temporarily disrupt ordinary patterns of perception, self-reference and cognition.

Those biological and psychological effects could potentially interact.

The pharmacology might create conditions for change.

The experience might influence what psychological change occurs within those conditions.

This interactive model remains unproven.

But it provides a framework capable of accommodating both the biological evidence and the subjective phenomena reported by patients.

What Would a Non-Hallucinogenic Psychedelic Tell Us?

One of the most fascinating ways to test the importance of subjective experience may come from an unexpected direction.

Researchers are developing compounds intended to reproduce some of the molecular actions associated with psychedelic drugs while reducing or eliminating their profound psychoactive effects.

If a non-hallucinogenic compound eventually produces therapeutic outcomes comparable with a strongly psychoactive psychedelic, that would strengthen the argument that the altered experience itself may not be necessary.

If, however, compounds producing profound subjective experiences consistently produce therapeutic effects that comparable non-hallucinogenic approaches cannot reproduce, the experiential hypothesis would become harder to ignore.

The development of these compounds may therefore help answer one of psychedelic medicine's most fundamental questions:

Do we need the trip?

Does the Setting Shape the Experience?

If subjective experience matters, another question immediately follows.

What shapes the subjective experience?

Psychedelic research has long emphasized concepts such as set and setting—the psychological state of the individual and the environment in which the experience occurs.

Ketamine treatment raises similar questions.

Could music matter?

The physical environment?

Preparation?

Expectation?

Human presence?

Therapeutic support?

Intention?

These variables are plausible.

They should not be treated as established mechanisms simply because they intuitively make sense.

For example, a secondary analysis of a randomized trial involving ketamine with psychological support found substantial psychedelic-like experiences among participants but did not find significant differences in therapeutic outcomes or psychedelic-experience intensity between music and matched non-music conditions. (Montreal trial analysis)

That does not demonstrate that music is irrelevant.

It demonstrates how difficult these variables are to isolate.

Environment may influence experience.

Whether particular environmental elements reliably improve clinical outcomes remains a scientific question.

Should Treatment Try to Produce a Mystical Experience?

At present, the evidence does not justify a universal conclusion that clinicians should attempt to induce a particular level of dissociation or mystical experience.

Dose, route, medical history, psychiatric history, medications, response and safety considerations are clinical matters.

They belong with appropriately qualified treating professionals.

This distinction is especially important because racemic ketamine is FDA-approved as an anesthetic, not as a treatment for psychiatric disorders. Its psychiatric use is off-label.

The scientific question explored here is different.

It is whether the nature of the subjective experience might ultimately prove to be one variable contributing to therapeutic response.

That possibility deserves investigation.

It is not yet a dosing protocol.

Experience Is Data—But Not Proof

Modern medicine is understandably cautious about subjective reports.

Subjective experience is difficult to standardize.

It is influenced by memory, expectation, language, culture and interpretation.

But psychiatry itself depends heavily upon subjective phenomena.

Depression.

Anxiety.

Hopelessness.

Meaning.

Fear.

Connection.

These are not measured like blood glucose.

The challenge is therefore not to choose between subjective experience and scientific evidence.

It is to study subjective experience scientifically.

That means using validated measures.

Collecting outcomes systematically.

Testing hypotheses prospectively.

Separating correlation from causation.

And being willing to discover that an observation we find compelling may ultimately be wrong.

What We Know

Ketamine reliably produces altered states of consciousness in many people, although their nature and intensity vary substantially.

Ketamine can produce mystical-type experiences, including experiences involving unity, transcendence and altered self-perception.

Some studies have found relationships between ketamine-induced altered states and therapeutic outcomes.

Others have not.

Across 29 studies included in a recent systematic review, slightly more than half reported a positive relationship between altered states and clinical outcomes, while nearly as many reported no relationship.

Conventional measures of dissociation such as total CADSS scores have not consistently predicted antidepressant response.

Different components of dissociation may nevertheless have different relationships with outcomes; some studies have identified associations involving depersonalization or derealization.

What We Don't Know

We do not know whether mystical-type experiences cause better therapeutic outcomes.

We do not know whether a certain depth of altered consciousness is necessary for antidepressant response.

We do not know whether ordinary dissociation and profound mystical experience represent therapeutically different phenomena.

We do not know how much of ketamine's effect is biological, experiential or produced by an interaction between the two.

We do not know whether deliberately attempting to intensify the subjective experience improves outcomes.

And we do not yet know which aspects of an altered state—if any—are therapeutically important.

The Question That Remains

Our observations at Ketamine Lounge have convinced us that the subjective experience deserves to be taken seriously.

They have not convinced us that we have already explained it.

There is an important difference.

The scientific literature now gives us good reason to move beyond asking simply whether ketamine causes dissociation.

It clearly can.

The more interesting questions concern what kind of altered state occurs, how deeply ordinary consciousness changes and whether particular dimensions of that experience have therapeutic significance.

Perhaps ketamine's antidepressant effects will ultimately prove to reside primarily in pharmacology.

Perhaps profound subjective experiences contribute independently.

Perhaps biology opens a window while experience helps determine what passes through it.

We don't yet know.

But consider two people receiving the same molecule.

One remains largely anchored to ordinary consciousness.

The other temporarily loses their familiar boundaries of self, time and space and emerges describing an experience of profound connection and meaning.

Did they receive the same treatment?

Sources & Further Reading

This article draws on peer-reviewed studies and systematic reviews examining ketamine-induced altered states of consciousness, dissociation, mystical-type experience and antidepressant outcomes.

Altered states and outcomes: Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices. The review reports the 29-study totals discussed above.

Dissociation and esketamine: Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine. A post hoc analysis of 576 participants from two trials; statistical association should not be confused with clinical importance.

Mystical experiences in veterans: Ketamine-Occasioned Mystical Experience in Veterans with Treatment-Resistant Depression: A Retrospective Exploratory Analysis. Observational session data, not proof that mystical experiences cause improvement.

The 39-patient analysis: Sympathetic activation but not dissociation linked to ketamine’s sustained antidepressant effect. An open-label, post hoc analysis with response assessed at Day 7.

Music and psychological support: Montreal Model randomized-trial secondary analysis. Music and matched non-music groups did not differ in the reported therapeutic outcomes or psychedelic experiences.

Because this remains an evolving area of research, associations between subjective experience and treatment response should not be interpreted as establishing causation.

Readers should consider the publication dates and limitations of the cited studies when interpreting emerging evidence.

Disclosure

Dane Jackman is a founder of Ketamine Lounge. Observations attributed to Ketamine Lounge in this article reflect experiential observations from the treatment environment and should not be interpreted as findings from a controlled clinical study.

Editorial Note

References to mystical, spiritual or transcendent experiences describe subjective reports and do not imply scientific validation of metaphysical interpretations. The relationship between ketamine-induced altered states and therapeutic outcomes remains under investigation.

Medical Disclaimer

This article is provided for informational and educational purposes only and does not constitute medical advice, diagnosis or treatment. Racemic ketamine is FDA-approved as an anesthetic but is not FDA-approved for psychiatric disorders; psychiatric use is off-label. Treatment decisions, including dose and route of administration, should be made by appropriately qualified healthcare professionals.